Author(s): Pan HF, Li XP, Zheng SG, Ye DQ, Pan HF, Li XP, Zheng SG, Ye DQ
Abstract Share this page
Abstract Interleukin-22 (IL-22) is an IL-10 family cytokine member that was recently discovered to be mainly produced by Th17 cells. Previous studies have indicated the importance of IL-22 in host defense against Gram-negative bacterial organisms (in gut and lung). Recently, there is emerging evidence that IL-22 is involved in the development and pathogenesis of several autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), Sjögren's syndrome (SS) and psoriasis. Therapeutics targeting IL-22 therefore may have promise for treating various autoimmune diseases. In this review, we discuss the recent progression of the involvement of IL-22 in the development and pathogenesis of autoimmune diseases, as well as its clinical implications and therapeutic potential. Copyright © 2012 Elsevier Ltd. All rights reserved.
This article was published in Cytokine Growth Factor Rev
and referenced in Journal of Neurology & Neurophysiology